seed
Stage
About
Praeventix is a biopharmaceutical company developing selective 5-HT7 receptor antagonist therapeutics, including a topical treatment candidate PRA-523 for chronic pruritus and researching other serotonergic-driven disorders such as inflammatory bowel disease and cocaine use disorder.
Explore Praeventix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.